Log in to search using one of your social media accounts:


Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.

CONCLUSIONS: Despite the results achieved at somatic levels by other researchers, these were not confirmed in our study at the germline level. Our results show the need to establish more predictive CpG sites in the BRCA promoter regions to optimize the MS-MLPA assay for the detection of germline hypermethylation as an effective pre-screening tool for whole-BRCA genetic analysis in HBOC, because we can not rule out the existence of germline promoter hypermethylation in BRCA. PMID: 29404838 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Oncol Source Type: research

Related Links:

This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - Category: Internal Medicine Authors: Tags: Review ‐Symposium Source Type: research
Authors: Suh DH, Kim M, Lee KH, Eom KY, Kjeldsen MK, Mirza MR, Kim JW Abstract In 2017, 10 topics were selected as major clinical research advances in gynecologic oncology. For cervical cancer, efficacy and safety analysis results of a 9-valent human papillomavirus (HPV) vaccine and long-term impact of reduced dose of quadrivalent vaccine were updated. Brief introduction of KEYNOTE trials of pembrolizumab, a monoclonal antibody that blocks the interaction between programmed death (PD)-1 and its ligands, PD-L1 and PD-L2, followed. Tailored surveillance programs for gynecologic cancer related with Lynch syndrome and ...
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
Conclusions: Although an uncommon tumor, MMMTs are often found in women with breast cancer. Despite this finding, BRCA1 or BRCA2 germline mutations are not common in this population. Precis: Ovarian MMMTs are frequently found in women with cancer but are not frequently associated with defects in BRCA1 or BRCA2.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Gynecologic Source Type: research
Authors: Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, Takahashi K, Totsuka H, Ogiwara H, Hirose S, Kono K, Tamura K, Okamoto A, Kinoshita T, Kato T, Kohno T Abstract There has been little improvement in the prognosis for adolescent and young adult (AYA) tumor patients. Hence, there is an urgent need to understand the etiology of tumor development and identify actionable gene aberrations to improve prevention and therapy. Here, 76 sporadic tumors (48 breast, 22 ovarian, and six uterine) from 76 AYA females (age range, 25-39 years) were subjected to whol...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
BOSTON (CBS) – A new study finds that a higher risk of ovarian cancer can be passed from father to daughter. Researchers at the Roswell Park Cancer Institute in Buffalo, NY looked at data from the Familial Ovarian Cancer Registry and discovered a genetic mutation passed from a father to his daughter on the X-chromosome that puts her at higher risk for ovarian cancer. The research team is looking for what the Ovarian Cancer gene looks like. (WBZ-TV) When we think of hereditary ovarian cancer, we often think of the BRCA genes that raise the risk of both ovarian cancer and breast cancer in first degree female relatives,...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health Local News Seen On WBZ-TV Syndicated Local Cancer Risk Dr. Mallika Marshall Genes ovarian cancer Source Type: news
This article aims to summarize advanced studies concerning protective effects of GnRH-a on ovarian functions in the setting of breast cancer under chemotherapy. PMID: 29466689 [PubMed - in process]
Source: Discovery Medicine - Category: Research Tags: Discov Med Source Type: research
ConclusionIn India, socioeconomic inequality limiting access to treatment is a major factor towards increased cancer burden; therefore, incorporation of a cost-effective and comprehensive multi-gene test will be helpful in ensuring widespread implementation of genetic screening in the clinical practice for hereditary breast and/or ovarian cancers.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionGnRHa may have a protective effect against the development of POF after gonadotoxic chemotherapy; however, the duration of benefit is unclear and requires further study.
Source: Journal of Assisted Reproduction and Genetics - Category: Reproduction Medicine Source Type: research
SummarySurvival after childhood cancer has improved substantially; therefore, the number of childhood cancer survivors is increasing. This growing population of childhood cancer survivors, however, is at risk of a  spectrum of adverse health outcomes. Unfortunately, until now, there was a lack of comprehensive follow-up recommendations. The purpose of this article is to provide information on recently developed harmonized evidence-based guidelines on surveillance investigations to screen for the early detec tion of breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian failure in childhood canc...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: We observed a high adherence to counselling, genetic testing and active surveillance by men belonging to hereditary BC families. Male carriers of pathogenic DNA variants are at risk for several cancers and should be included in prospective follow-up studies. PMID: 29456621 [PubMed]
Source: Ecancermedicalscience - Category: Cancer & Oncology Tags: Ecancermedicalscience Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | Ovarian Cancer | Ovaries | Study